Wednesday, January 29, 2020

 


Johnson & Johnson
(NYSE: JNJ) Add to Watchlist
$149.50
+0.75 (+0.50%)
as of Jan 28, 2020

Last 149.50
Change +0.75 (+0.50%)
Open 148.46
Prev. Close 148.75
Today's Range
148.15 150.57
52wk Range
126.10 150.57
Volume 7,336,600
Avg Volume 6,813,885
Sector SIC-2834 Pharmaceutical Preparations

Recent Headlines
INVOKANA(®) is the only diabetes treatment in Canada approved to treat this patient group  (full story)
JNJ: 149.50 (+0.75)
In the Phase 3 pivotal trial, nearly 44 per cent of patients receiving STELARA(®) subcutaneous (SC) injections every 8 weeks were in clinical remission at one year  (full story)
JNJ: 149.50 (+0.75)
The "Stroke Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.  (full story)
AMGN: 224.84 (+1.89), BMY: 64.81 (+1.11), JNJ: 149.50 (+0.75)
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has approved the expanded use of STELARA(R) (ustekinumab) for the treatment of paediatric patients (ages 6-11) with moderate to severe plaque psoriasis. Ustekinumab was previously approved for  (full story)
JNJ: 149.50 (+0.75)
Cynosure, LLC, a leader in medical aesthetics systems and technologies, today announced new leadership appointments to accelerate the company's business transformation and growth plans.  (full story)
JNJ: 149.50 (+0.75)
Performance Comparison
Name Today 3-Month 1-Year
JNJ +0.50% +13.89% +15.90%
DJIA +0.66% +3.38% +17.10%
S&P 500 +1.01% +5.89% +23.92%

Key Statistics
Annual EPS 6.78
Dividend & Yield 0.95 (2.56%)
P/E Ratio 17.09
Market Capitalization, $K 390,359,344
Weighted Alpha +14.80
Standard Deviation +1.08
Profit Margin 18.32%
Beta 0.71

Growth Rates
YTD +2.49%
1-Year +11.40%
3-Year +31.56%
5-Year +47.87%
10-Year +137.83%
© 2020 Market data provided and hosted by Barchart Market Data Solutions. Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.